Immunohistochemical expression of retinoblastoma protein and p16 in renal cell carcinoma

Urologia Internationalis

Volumn 86, Issue 1, 2011, Pages 60-67

  Maruschke, M ^a   Thur, S ^a   Kundt, G ^b   Nizze, H ^a   Hakenberg, O W ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Medicine and Ageing Research   (Germany)

Author keywords

p16; Renal cell carcinoma; Retinoblastoma protein

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PARAFFIN; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; NEPHRECTOMY; PARTIAL NEPHRECTOMY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CELL CYCLE; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RETINOBLASTOMA PROTEIN;

EID: 79951809298     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320510     Document Type: Article

References (35)

1. Massague J: G 1 cell-cycle control and cancer. Nature 2004; 432: 298-306.
2. McConnell BB, Gregory FJ, Stott FJ, Hara E, Peters G: Induced expression of p16 INK4a inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin- CDK-inhibitor complexes. Mol Cell Biol 1999; 19: 1981-1989. (Pubitemid 29098256)
3. Jiang H, Chou HS, Zhu L: Requirement of cyclin E-Cdk2 inhibition in p16 INK4a -mediated growth suppression. Mol Cell Biol 1998; 18: 5284-5290. (Pubitemid 28388112)
4. Hedberg Y, Ljungberg B, Roos G, Landberg G: Retinoblastoma protein in human renal cell carcinoma in relation to alterations in G 1 /S regulatory proteins. Int J Cancer 2004; 109: 189-193. (Pubitemid 38240919)
5. Gill RM, Slack R, Kiess M, Hamel PA: Regulation of expression and activity of distinct pRb, E2F, D-type cyclin, and CKI family members during terminal differentiation of p19 cells. Exp Cell Res 1998; 244: 157-170. (Pubitemid 28480864)
6. Semczuk A, Jakowicki JA: Alterations of pRb1-cyclin D1-cdk4/6-p16 INK4A pathway in endometrial carcinogenesis. Cancer Lett 2004; 203: 1-12. (Pubitemid 37506078)
7. Tort F, Bartkova J, Sehested M, Orntoft T, Lukas J, Bartek J: Retinoblastoma pathway defects show differential ability to activate the constitutive DNA damage response in human tumorigenesis. Cancer Res 2006; 66: 10258-10263. (Pubitemid 44799741)
8. le Frère-Belda MA, Gil Diez de Medina S, Daher A, Martin N, Albaud B, Heudes D, Abbou CC, Thiery JP, Zafrani ES, Radvanyi F, Chopin D: Profiles of the 2 INK4a gene products, p16 and p14 ARF , in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status. Hum Pathol 2004; 35: 817-824. (Pubitemid 38903074)
9. Drayton S, Brookes S, Rowe J, Peters G: The significance of p16INK4a in cell defenses against transformation. Cell Cycle 2004; 3: 611-615. (Pubitemid 40278203)
10. Brambilla E, Moro D, Gazzeri S, Brambilla C: Alterations of expression of Rb, p16 INK4A and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol 1999; 188: 351-360. (Pubitemid 29327432)
11. Malusecka E, Zborek A, Krzyzowska-Gruca S: Changes in expression of pRb, p16 and cyclin D1 in non-small cell lung cancer: an immunohistochemical study. Folia Histochem Cytobiol 1999; 37: 19-24. (Pubitemid 29067625)
12. Ko E, Kim Y, Lee BB, Han J, Song SY, Shim YM, Park J, Kim DH: Relationship of phospho- pRb (Ser-807/811) level to exposure to tobacco smoke in primary non-small cell lung cancer. Cancer Lett 2009; 274: 225-232.
13. Akin H, Yilmazbayhan D, Kiliçaslan Z, Dilege S, Doǧan O, Toker A, Kalayci G: Clinical significance of p16 INK4A and retinoblastoma proteins in non-small-cell lung carcinoma. Lung Cancer 2002; 38: 253-260. (Pubitemid 35341799)
14. Yuan J, Knorr J, Altmannsberger M, Goeckenjan G, Ahr A, Scharl A, Strebhardt K: Expression of p16 and lack of pRB in primary small cell lung cancer. J Pathol 1999; 189: 358-362. (Pubitemid 29489220)
15. Mohamed S, Yasufuku K, Hiroshima K, Nakajima T, Yoshida S, Suzuki M, Sekine Y, Shibuya K, Iizasa T, Farouk A, Fujisawa T: Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer. Cancer 2007; 109: 2506-2514. (Pubitemid 46906470)
16. Ikuerowo SO, Kuczyk MA, von Wasielewski R, Shittu OB, Jonas U, Machtens S, Serth J: p16INK4a expression and clinicopathologic parameters in renal cell carcinoma. Eur Urol 2007; 51: 732-737.
17. Lipponen P, Eskelinen M, Syrjänen K: Expression of tumour-suppressor gene Rb, apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma. Br J Cancer 1995; 71: 863-867.
18. Walther MM, Gnarra JR, Elwood L, Xu HJ, Florence C, Anglard P, Hu SX, King C, Trahan E, Hurley K, et al: Loss of heterozygosity occurs centromeric to RB without associated abnormalities in the retinoblastoma gene in tumors from patients with metastatic renal cell carcinoma. J Urol 1995; 153: 2050-2054.
19. Haitel A, Wiener HG, Neudert B, Marberger M, Susani M: Expression of the cell cycle proteins p21, p27, and pRb in clear cell renal cell carcinoma and their prognostic significance. Urology 2001; 58: 477-481. (Pubitemid 32816374)
20. Presti JC Jr, Reuter VE, Cordon-Cardo C, Motzer RJ, Albino AP, Jhanwar SC, Nanus DM: Expression of the retinoblastoma gene product in renal tumors. Anticancer Res 1996; 16: 549-556. (Pubitemid 26181980)
21. Xu HJ, Hu SX, Benedict WF: Lack of nuclear RB protein staining in G 0 /middle G 1 cells: correlation to changes in total RB protein level. Oncogene 1991; 6: 1139-1146. (Pubitemid 21924200)
22. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 4525-4530.
23. Bird A: The essentials of DNA methylation. Cell 1992; 70: 5-8.
24. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5′CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995; 1: 686-692.
25. Kawada Y, Nakamura M, Ishida E, Shimada K, Oosterwijk E, Uemura H, Hirao Y, Chul KS, Konishi N: Aberrations of the p14 ARF and p16 INK4a genes in renal cell carcinomas. Jpn J Cancer Res 2001; 92: 1293-1299. (Pubitemid 34036892)
26. Hodges A, Talley L, Gokden N: Human papillomavirus DNA and P16 INK4A are not detected in renal tumors with immunohistochemistry and signal-amplified in situ hybridization in paraffin-embedded tissue. Appl Immunohistochem Mol Morphol 2006; 14: 432-435. (Pubitemid 44813704)
27. Vidaurreta M, Maestro ML, Sanz-Casla MT, Maestro C, Rafael S, Veganzones S, Moreno J, Blanco J, Silmi A, Arroyo M: Inactivation of p16 by CpG hypermethylation in renal cell carcinoma. Urol Oncol 2008; 26: 239-245. (Pubitemid 351608573)
28. Sanz-Casla MT, Maestro ML, del Barco V, Zanna I, Moreno J, Vidaurreta M, Almansa I, Fernández C, Blanco J, Maestro C, Resel L: Loss of heterozygosity and methylation of p16 in renal cell carcinoma. Urol Res 2003; 31: 159-162. (Pubitemid 36962022)
29. Omura-Minamisawa M, Diccianni MB, Chang RC, Batova A, Bridgeman LJ, Schiff J, Cohn SL, London WB, Yu AL: p16/p14 ARF cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease. Clin Cancer Res 2001; 7: 3481-3490. (Pubitemid 33069984)
30. Eshkoor SA, Ismail P, Rahman SA, Oshkour SA: p16 gene expression in basal cell carcinoma. Arch Med Res 2008; 39: 668-673.
31. Vijayalakshmi N, Selvaluxmi G, Majhi U, Rajkumar T: Alterations found in p16/Rb/cyclin D1 pathway in the dysplastic and malignant cervical epithelium. Oncol Res 2007; 16: 527-533. (Pubitemid 351211325)
32. Jedpiyawongse A, Homcha-em P, Karalak A, Srivatanakul P: Immunohistochemical overexpression of p16 protein associated with cervical cancer in Thailand. Asian Pac J Cancer Prev 2008; 9: 625-630.
33. Li AF, Li AC, Tsay SH, Li WY, Liang WY, Chen JY: Alterations in the p16 INK4a /cyclin D1/RB pathway in gastrointestinal tract endocrine tumors. Am J Clin Pathol 2008; 130: 535-542.
34. Rosenblatt R, Jonmarker S, Lewensohn R, Egevad L, Sherif A, Kälkner KM, Nilsson S, Valdman A, Ullén A: Current status of prognostic immunohistochemical markers for urothelial bladder cancer. Tumour Biol 2008; 29: 311-322.
35. Richmond-Sinclair NM, Lee E, Cummings MC, Williamson R, Muller K, Green AC, Hayward NK, Whiteman DC: Histologic and epidemiologic correlates of P-MAPK, Brn-2, pRb, p53, and p16 immunostaining in cutaneous melanomas. Melanoma Res 2008; 18: 336-345.